Effect of the Hepatoprotective Drug Liv. 52 on Liver Damage
Doc. MUDr. M. Kalab, T. Krechler Internal Clinic of the Medical Faculty of the Charles University in Prague and The Military Faculty Hospital in Prague.
In the ultrasonic measurement of anteroposterior (AP) size of the right lobe of liver, was done after treatment, where there was significant diminishing (Graph No. 7).
Liv.52 has thus contributed to improvement in some important clinical symptoms and biochemical parameters, especially those that were not physiologically normal during the year of medication.
DISCUSSION
The spectrum of current medicinally utilized hepatoprotectives is small. It concerns routinely used preparations similar to Silimarin: Flavobion, Legalon and Hepabene. The effectiveness of hepatoprotectives is a matter for continuous discussion, which concerns substances that effect metabolism or reinforce membranes of hepatocytes. The subjective state of patients is often improved by this treatment, even if it is partly a placebo effect. At any rate, these medications improve the patients holistically and also build up confidence of the patients towards their physician.
Clinical studies were carried out with Liv.52 for patients effected with liver damage (1), and cirrhosis of liver (1,2). Accordingly, tests on animals proved the effect of toxic damage of tetrachloride on liver (3) and the protective effect of Liv.52 against beryllium toxicity(4). The mechanism of effect is unclear. In human medicine, Liv.52’s effects on infectious hepatitis (5), chronic damage of liver with alcohol (1,6), steatosis of liver (7), initial state of liver cirrhosis (2), chronic active hepatitis (8), cases of anorexia and non specific cases of dyspepsia have been cited. Physicians in India published most of these clinical studies. In Czech Republic, Liv.52 was first observed in 1980s when patients brought it from Switzerland, USA, India, Australia. At the beginning of the 1990s, this preparation appeared in the market in some pharmacies and was distributed through other means.
The problem of following up the effect of Liv.52 with a homogenous group of patients in Czech Republic was that the preparation was not in current distribution, as it was not registered as a medicine, but only as a supplement. Patients who were followed up bought these medicines on their own and not through the prescription of a physician. The results in the improvement of the subjective state and in many laboratory parameters are promising, and as a consequence there is a demand for this medicine. Liv.52 is well tolerated, non-toxic and there are no side effects.
LITERATURE
1. Lotterer, E. and Etzel, R. Pilotstudie einer kontrollierten klinischen Prufung von Liv.52 bei Patienten mit alkoholischer Leberzirrhose Forsch. Komplementarmed. Med., (1995): (2), 12.
2. Patney, N.L., Jasuja, R.K. and Kumar, A. Managements of steatorrhoea of cirrhosis of the liver by indigenous drug – Liv.52. Probe (1976): (XV), 3, 164-179.
3. Goel, A., Dhawan, D.K. and Gaumtam, C.S. Influence of Liv.52 on carbon tetrachloride – included hepatotoxicity: A biochemical study. Probe (1993): (XXXII), 4, 286-288.
4. Mathur, R., Mathur, S. and Prakash, A.O. Liv.52 protection against berrylium toxicity in female albino rats. Reprod. Toxicol. (1989): 3, 249.
5. Agarwal, W.K., Sareen, M.: Clinical trial of Liv.52 drops in infective hepatitis. Probe (1976): (XV), 3, 112.
6. De Souza, A., Gangdev, P., Sinorawala, A. and Agarwal, M. Liv.52 in alcoholism. J. Comm. Psychiat. (1989): (12), 23
7. Sule, C.R., Sathe, P.M.: Liv.52 in the treatment of ascites. Curr. Med. Pract. (1957): (1), 42.
8. Dasgupta, M., Mukhersee, A.B.: Chronic active hepatitis. J. Ind. Med. Prof. (1971): (18), 8097
Refference: http://www.himalayahealthcare.com/pdf_files/liv196.pdf
Copyrights © 2009 healthyliver.co.uk